Aspectos clínico-econômicos da quimioterapia adjuvante no câncer de mama HER-2 positivo

Martins, Sandro José; Yamamoto, Crystina Aoki

doi:10.1590/s0104-42302008000600012

Cited by 7 publications

(4 citation statements)

References 13 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…monotherapy for one year. However, such values are very significant for countries such as Brazil, where health resources are scarce, access to mammography is precarious and the diagnosis of breast cancer is late (9) .…”

Section: Resultsmentioning

confidence: 99%

“…By addressing clinical and economic aspects of adjuvant chemotherapy in HER2-positive breast cancer, the authors claim that the medical profession and society should pay attention not only to the eligibility criteria or differences in efficacy between the various treatment protocols in use, but also, the economic implications of individual therapeutic decisions for the health care system (9) .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Procedures’ costs related to outpatient chemotherapy treatment of women suffering from breast cancer

Nobrega

Lima

2014

Rev. esc. enferm. USP

View full text Add to dashboard Cite

Rev Esc Enferm RESUmEnObjetivo: Identificar el costo directo de los procedimientos relacionados con el tratamiento de quimioterapia ambulatoria para las mujeres con cáncer de mama. Método: Investigación cuantitativa, del tipo de estudio de caso, realizada en el ambulatorio de quimioterapia de un hospital privado Se calculó el costo total mediante la multiplicación del tiempo dedicado por los profesionales involucrados en el proceso, por el costo unitario de la mano de obra directa, sumándose al costo de los materiales, fár-macos y soluciones. Para la realización de los cálculos se utilizó la moneda brasileña (R$). Resultados: El costo total medio, por sesión de quimioterapia, correspondió a R$ 1.783,01 (100%), de los cuales R$ 1.671,66 (93,75%) fueron con fármacos, R$ 74,98 (4,21%) con materiales, R$ 28,49 (1,60%) con mano de obra y R$ 7,88 (0,44%) con soluciones. Conclusión: Los resultados logrados podrán servir como base para las discusiones y la toma de decisiones con respecto a la gestión de los costos relacionados con la quimioterapia, con vistas a la reducción de los gastos y la eliminación de los desperdicios, sin perjuicios a la atención prestada. dEScRiPtoRESNeoplasias de la mama Quimioterapia Costos de la Atención en Salud Costos y análisis de costo Enfermería oncológica. RESUmoObjetivo: Identificar o custo direto de procedimentos relacionados ao tratamento quimioterápico ambulatorial de mulheres portadoras de câncer de mama. Método: Pesquisa quantitativa, do tipo estudo de caso, realizada no ambulatório de quimioterapia de um hospital privado. O custo total foi calculado multiplicando-se o tempo despendido pelos profissionais envolvidos nos procedimentos terapêu-ticos, pelo custo unitário da mão de obra direta, somando-se ao custo dos materiais, fármacos e soluções. Para a realização dos cálculos, utilizou-se a moeda brasileira (R$). Resultados: O custo total médio, por sessão de quimioterapia, correspondeu a R$ 1.783,01 (100%), sendo R$ 1.671,66 (93,75%) com fármacos, R$ 74,98 (4,21%) com materiais, R$ 28,49 (1,60%) com mão de obra e R$ 7,88 (0,44%) com soluções. Conclusão: Os resultados obtidos poderão subsidiar discussões e tomadas de decisões em relação à gestão dos custos relativos à quimioterapia visando à redução dos gastos e a eliminação dos desperdícios, sem prejuízos ao atendimento prestado. dEScRitoRESNeoplasias da mama Quimioterapia Custos de cuidados de saúde Custos e análise de custo Enfermagem oncológica AbStRActObjective: To identify the direct cost of procedures related to an outpatient chemotherapy treatment for women with breast cancer. Method: This is a quantitative research, using the case study methodology, performed in an outpatient chemotherapy of a private hospital. The total cost was calculated by multiplying the time spent by professionals involved in therapeutic procedures, the unit cost of direct labor, adding to the cost of materials, drugs and solutions. For performing the calculations, we used the Brazilian currency (R$). Results: The average total cost per chemotherapy...

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Procedures’ costs related to outpatient chemotherapy treatment of women suffering from breast cancer

Nobrega

Lima

2014

Rev. esc. enferm. USP

View full text Add to dashboard Cite

show abstract

“…Despite the fact that the scientific literature has contained evidence that such screening reduces mortality since 1993 ( 1 ), those two studies (a partial HEE and a full HEE) were published only in 2005 and 2010, respectively. Similarly, the breast cancer drugs anastrozole and trastuzumab, approved by the United States Food and Drug Administration (FDA) in 1996 and 1998, respectively, were not evaluated in HEEs related to Brazil until 2009 and 2008, respectively ( 27 , 33 ). Although HEEs related to breast cancer have been conducted only recently in Brazil, as have those related to other aspects of oncology, these results indicate the importance of breast cancer, not to mention that of nonmelanoma skin cancer, the former representing the most common type of neoplasia among women in developed and developing countries alike, as well as being the leading cause of cancer death among women worldwide ( 2 ).…”

Section: Discussionmentioning

confidence: 99%

Health Economic Evaluations of Cancer in Brazil: A Systematic Review

Campolina

et al. 2018

Front. Public Health

View full text Add to dashboard Cite

Background: A large number of health economic evaluation (HEE) studies have been published in developed countries. However, Brazilian HEE literature in oncology has not been studied. Objective: To investigate whether the scientific literature has provided a set of HEE in oncology capable of supporting decision making in the Brazilian context.Methods: A systematic review was conducted to identify and characterize studies in this field. We searched multiple databases selecting partial and full HEE studies in oncology (1998-2013).Results: Fifty-five articles were reviewed, of these, 33 (60%) were full health economic evaluations. Type of cancers most frequently studied were: breast (38.2%), cervical (14.6%), lung (10.9%) and colorectal (9.1%). Procedures (47.3%) were the technologies most frequently evaluated. In terms of the intended purposes of the technologies, most (63.6%) were treatments. The majority of the incremental cost-effectiveness ratios (ICERs) reported have been below the cost-effectiveness threshold suggested by the World Health Organization (WHO).Conclusions: There has been an increase in the number of HEEs related to cancer in Brazil. These studies may support decision-making processes regarding the coverage of and reimbursement of healthcare technologies for cancer treatment in Brazil.

show abstract

“…Trastuzumab was included in the SUS in 2012, recommended for the treatment of HER2-positive early-stage breast cancer after surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (when applicable), requiring confirmation of HER-2 status before treatment [13]. There is solid scientific evidence favoring the use of Trastuzumab to treat women with HER2-positive breast cancer [14].…”

Section: Introductionmentioning

confidence: 99%

Public engagement in health technology assessment in Brazil: the case of the Trastuzumab public consultation

Carvalho

Sousa

Barreto

et al. 2019

BMC Health Serv Res

View full text Add to dashboard Cite

BackgroundPublic engagement in health technology assessment (HTA) is increasing worldwide. There are several forms of public engagement and it is not always possible to determine which stakeholders participate in the HTA process and how they contribute. Our objective was to investigate which types of social representatives contributed to the public consultation on the incorporation of Trastuzumab for early-stage breast cancer treatment within the public health system in Brazil, held in 2012 by the National Committee for Health Technology Incorporation (CONITEC).MethodsA mixed methods approach was used to analyze social representativeness and the composition of the corpus from the public consultation, which consisted of 127 contributions. Three types of analysis were performed using IRaMuTeQ software: classic lexical analysis, descending hierarchical classification and specificities analysis. The contributions were clustered according to the main categories of discourse observed, into four social representation categories: 1) patient representation/advocacy; 2) pharmaceutical industry/advocacy; 3) healthcare professionals; and 4) individual contributions.ResultsCategory 1 contained words related to increased survival due to use of the drug and a low score for words pertaining to studies on Trastuzumab. The word “safety” obtained a positive score only in category 2, which was also the only category that exhibited a negative score for the word “risk”. Category 3 displayed the lowest scores for “diagnosis” and “safety”. The word “efficacy” had a negative score only in category 4.ConclusionsEach category exhibited different results for words related to health systems and to key concepts linked to HTA. Our analysis enabled the identification of the most prominent contributions for each category. Despite the promising results obtained, further research is needed to validate this software for use in analyzing public contributions.

show abstract

Aspectos clínico-econômicos da quimioterapia adjuvante no câncer de mama HER-2 positivo

Cited by 7 publications

References 13 publications

Procedures’ costs related to outpatient chemotherapy treatment of women suffering from breast cancer

Procedures’ costs related to outpatient chemotherapy treatment of women suffering from breast cancer

Health Economic Evaluations of Cancer in Brazil: A Systematic Review

Public engagement in health technology assessment in Brazil: the case of the Trastuzumab public consultation

Contact Info

Product

Resources

About